Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2017

Published: Jul, 2017 | Pages: 88 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2017, provides an overview of the Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline landscape.

Uterine fibroids are benign tumors that originate in the uterus (womb). Although they are composed of the same smooth muscle fibers as the uterine wall (myometrium), they are much denser than normal myometrium. Uterine fibroids are usually round. The most common symptoms of uterine fibroids include heavy menstrual bleeding, prolonged menstrual periods seven days or more of menstrual bleeding, pelvic pressure or pain, frequent urination, difficulty emptying your bladder, constipation and backache or leg pains.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline guide also reviews of key players involved in therapeutic development for Uterine Leiomyoma (Uterine Fibroids) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 1, 1, 1, 5 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders).
- The pipeline guide reviews pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Uterine Leiomyoma (Uterine Fibroids) - Overview
Uterine Leiomyoma (Uterine Fibroids) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Uterine Leiomyoma (Uterine Fibroids) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Uterine Leiomyoma (Uterine Fibroids) - Companies Involved in Therapeutics Development
AbbVie Inc
Addex Therapeutics Ltd
Bayer AG
BioSpecifics Technologies Corp
Boryung Pharmaceutical Co Ltd
Dongkook Pharmaceutical Co Ltd
Kissei Pharmaceutical Co Ltd
Laboratoire HRA Pharma
Luye Pharma Group Ltd
Ogeda SA
Takeda Pharmaceutical Company Ltd
Uterine Leiomyoma (Uterine Fibroids) - Drug Profiles
collagenase clostridium histolyticum - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Activate Progesterone Receptor for Uterine Fibroids - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Endometriosis and Uterine Fibroids - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
elagolix sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EVE-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fezolinetant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KLH-2109 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
relugolix - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize FSH Receptor and LH Receptor for Women's Health - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Oncology and Uterine Fibroids - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
triptorelin acetate ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
triptorelin biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ulipristal acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ulipristal acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vilaprisan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VPE-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects
Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products
Uterine Leiomyoma (Uterine Fibroids) - Product Development Milestones
Featured News & Press Releases
Jul 03, 2017: Bayer starts Phase III study program with Vilaprisan in the treatment of symptomatic uterine fibroids
Jun 07, 2017: ObsEva Announces the Completion of a Phase 1 PK/PD Clinical Trial Evaluating Different Doses of OBE2109 and Add-Back Therapy
May 07, 2017: Myovant Sciences Announces Presentation of Positive Phase 2 Data for Relugolix in Women with Heavy Menstrual Bleeding and Uterine Fibroids at the Annual Meeting of the American Congress of Obstetricians and Gynecologists
Apr 25, 2017: ObsEva Initiates Phase 3 Clinical Program for OBE2109 in Uterine Fibroids
Apr 18, 2017: BioSpecifics Technologies Initiates Phase 1 Clinical Trial of XIAFLEX for Treatment of Uterine Fibroids
Apr 07, 2017: AbbVie Announces Positive Phase 2b Data Demonstrating Investigational Medicine Elagolix Significantly Reduced Heavy Menstrual Bleeding in Women with Uterine Fibroids
Jan 25, 2017: Myovant Sciences Initiates Phase 3 Clinical Program of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Jan 17, 2017: Allergan and Gedeon Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids
Nov 21, 2016: FIBRISTAL, The First And Only Medication Indicated For Uterine Fibroids, Receives Approval From Health Canada For Long Term Intermittent Treatment
Oct 17, 2016: Allergan to Present New Data Including Ulipristal Acetate at the American Society of Reproductive Medicine (ASRM) Scientific Congress and Expo in Salt Lake City
Oct 13, 2016: Latest clinical data on Bayer mid-stage candidate Vilaprisan to be presented at ASRM
Jul 19, 2016: EUROSCREEN opens US-IND for ESN364 on three Phase II trials
May 31, 2016: BioSpecifics Technologies Announces Publication of Encouraging Data for Uterine Fibroid Treatment with CCH in American Journal of Obstetrics & Gynecology
May 09, 2016: Allergan and Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids
Jan 28, 2016: AbbVie Initiates Enrollment in Phase 3 Clinical Program for Elagolix in Patients with Uterine Fibroids
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by AbbVie Inc, H2 2017
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Addex Therapeutics Ltd, H2 2017
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Bayer AG, H2 2017
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by BioSpecifics Technologies Corp, H2 2017
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2017
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Dongkook Pharmaceutical Co Ltd, H2 2017
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Kissei Pharmaceutical Co Ltd, H2 2017
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Laboratoire HRA Pharma, H2 2017
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Luye Pharma Group Ltd, H2 2017
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Ogeda SA, H2 2017
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017
Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects, H2 2017
Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products, H2 2017